{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:15:31Z","timestamp":1791778531403,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.3816\/clm.2007.s.016","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T21:06:16Z","timestamp":1221599176000},"page":"S150-S155","source":"Crossref","is-referenced-by-count":16,"special_numbering":"S4","title":["Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin\/Vincristine\/Dexamethasone Versus Doxorubicin\/Vincristine\/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma"],"prefix":"10.3816","volume":"7","author":[{"given":"Christopher A.","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.s.016_bib1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","article-title":"Multiple myeloma","volume":"336","author":"Bataille","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.016_bib2","series-title":"Cancer: Principles & Practice of Oncology","author":"DeVita","year":"2001"},{"issue":"suppl 3","key":"10.3816\/CLM.2007.s.016_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1634\/theoncologist.8-suppl_3-39","article-title":"Modifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide","volume":"8","author":"Hussein","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2007.s.016_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"10.3816\/CLM.2007.s.016_bib5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(89)91549-3","article-title":"Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma","volume":"2","author":"Samson","year":"1989","journal-title":"Lancet"},{"key":"10.3816\/CLM.2007.s.016_bib6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1200\/JCO.2004.05.111","article-title":"Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials","volume":"22","author":"Durie","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1989.tb06269.x","article-title":"VAD chemotherapy for refractory multiple myeloma","volume":"71","author":"Lokhorst","year":"1989","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.016_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CLM.2007.s.016_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2007.s.016_bib14","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.016_bib15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I","article-title":"Prognostic factors in multiple myeloma","volume":"36","author":"Alexanian","year":"1975","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.016_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CLM.2007.s.016_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2007.s.016_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/annonc\/mdg287","article-title":"Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma","volume":"14","author":"Dimopoulos","year":"2003","journal-title":"Ann Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T12:23:07Z","timestamp":1545740587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":18,"alternative-id":["S1557919011701305"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.s.016","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}